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Conjugation of therapeutics to human serum albumin (HSA) using
bromomaleimides represents a promising platform for half-life
extension. We show here that the Cys-34 crevice substantially
reduces the rate of serum stabilising maleimide hydrolysis in these
conjugates, necessitating reagent optimisation. This improved
reagent design is applied to the construction of an HSA-paclitaxel
conjugate, preventing drug loss during maleimide hydrolysis.
Human serum albumin (HSA) represents the most abundant
protein in blood plasma, and plays numerous roles including as
a transporter of fatty acids and various other endogenous and
exogenous ligands around the body. It represents an ideal candi-
date for use in drug delivery systems as it is highly soluble and
stable, has an extremely long circulatory half-life, and accumu-
lates in tumours due to the enhanced permeability and reten-
tion eﬀect.1,2 Several albumin based therapeutics have reached
the clinic. For example Abraxane®, which is a nanoparticle for-
mulation of paclitaxel with albumin, is used in the treatment of
breast, pancreatic and non-small cell lung cancers.3 Other strat-
egies exploited include the non-covalent association of drugs to
albumin, fusion proteins, and covalent conjugation.4
HSA contains Cys-34 as a convenient handle for site-selec-
tive chemical conjugation, and is commonly targeted with
maleimide reagents for the attachment of drugs.5–8 However,
such maleimide conjugates are now known to be unstable over
prolonged periods in vivo, undergoing retro-conjugate
additions to release the cargo from the protein.9–12 Whilst
hydrolysis of the maleimide can generate stable constructs,
this process can lead to concomitant loss of an amount of the
attached drug.9,13 To overcome this limitation we recently
described monobromomaleimides (MBMs)14 as a promising
platform for HSA conjugation (Scheme 1).13 By forming thio-
maleimides 1, which have maintained the conjugated double
bond and hence precluded any mechanistic possibility of
spontaneous deconjugation (no acidic α-hydrogen), we showed
that these conjugates undergo quantitative hydrolysis to aﬀord
serum stable maleamic acids 2.
To test the applicability of this approach to the construction
of albumin–drug conjugates, we targeted the attachment of
paclitaxel (PTX). PTX has poor solubility, and for clinical use
requires a formulation using polyethoxylated castor oil
(Cremophor EL) and ethanol, which are considered to contrib-
ute to side-eﬀects such as hypersensitivity reactions. The con-
jugation of PTX to albumin would preclude the need for such
formulations, whilst also oﬀering an extended in vivo half-life
and selective accumulation in tumours. Such albumin–PTX
conjugates have previously been targeted using sub-optimal
unselective lysine conjugation15,16 and cysteine conjugation
with unstable maleimide reagents.17 Notably PTX–albumin con-
jugates are commonly prepared as esters of the C-2′ PTX
hydroxyl,15,17 and hence are designed to release the free drug
through hydrolysis. As such it is even more important that the
albumin–drug attachment chemistry is robustly stable, to allow
careful analysis and interpretation of the PK of drug release.
Scheme 1 Previous work describing monobromomaleimides for
human serum albumin (HSA) conjugation.13
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To apply the MBM platform to such albumin–drug conju-
gates we identified that an improvement in the reagent design
was required. The previous protocol (Scheme 1) required a sta-
bilising hydrolysis be carried out at pH 9.0, 37 °C, overnight.
Such prolonged alkaline conditions are known to lead to
degradation of sensitive drugs such as PTX,18 and also to
hydrolyse ester pro-drugs.19 A dramatic acceleration in this
maleimide hydrolysis would be required to make this
approach broadly applicable, and our investigations to this
end are described.
It has been shown that antibody conjugates generated
using bromomaleimides with electron withdrawing C-2
(–CH2C(O)–) linkers undergo rapid hydrolysis in 1–2 h post
conjugation (pH 8.0–8.5, rt).20,21 To attempt to transfer this
simple hydrophilic linker design to albumin conjugates we
initially synthesised MBM-C-2-dansyl reagent 3. Dansyl was
chosen as its fluorescent properties are quenched by attached
maleimides, and then ‘turned-on’ by maleimide
hydrolysis.22,23 This compound would thus allow a clear read-
out of the rate of hydrolysis. Conjugation of this reagent to
HSA aﬀorded conjugate 4, with LCMS post-hydrolysis revealing
that unmodified protein and a double addition adduct were
also present as minor species (ESI Fig. S2 and S3†). Whilst
clearly in need of optimisation, an initial hydrolysis study was
carried out. MBM reagent 3, model cysteine adduct 5 and the
conjugate 4 were compared, leading in each case to the
expected increase in fluorescence at 559 nm (Fig. 1). Several
interesting observations can be made. The bromomaleimide is
∼4-fold more susceptible to hydrolysis than the thiomaleimide
conjugates, presumably due to the inductive electron-with-
drawing eﬀect of the bromine, which is consistent with the
eﬀect observed for dibromomaleimides (although to a reduced
magnitude).20,24 The next is that the HSA causes a ∼20-fold
decrease in the rate of hydrolysis of the attached thiomalei-
mide. This is likely due to the hydrophobic ∼10 Å crevice in
which Cys-34 resides serving a substantive protective role.5
Finally we noted that the hydrolysis of monothiomaleimides
demonstrates substantial regioselectivity, with a 7 : 1 ratio of
isomers (see ESI,† compares with 2.5 : 1 for the bromomalei-
mide). The carbonyl proximal to the thioether is hydrolysed
preferentially, thought to be due to a combination of inductive
activation and mesomeric deactivation of the two carbonyls
respectively.
To improve upon this initial design, we chose to incorpor-
ate a PEG spacer in future molecules, postulating that it would
improve the eﬃciency of the conjugation to the sterically hin-
dered Cys-34. We also identified that the thiomaleimide absor-
bance at 350 nm could be monitored to aﬀord the rate of con-
jugation, and its subsequent disappearance would reveal
hydrolysis,20 negating the requirement to have a fluorophore
attached. Pleasingly treatment of HSA with MBM 6 (2 equiv.)
led to extremely clean conjugation, with no unmodified HSA
or bis-modification (Fig. 2). Furthermore, monitoring the
increasing absorbance at 350 nm allowed us to identify that
the reaction was >99% complete after 10 min. This confirmed
the rapid nature of bromomaleimide HSA conjugation, despite
the relatively hindered location of Cys-34.
By monitoring the disappearance of the absorbance at
350 nm it was then possible to reveal the rates of hydrolysis of
the thiomaleimide conjugates at pH 8.0 (Fig. 3). It was interest-
ing to note that a simple ethylene glycol conjugate 7 showed
an initial ∼1.5 fold acceleration (entry 1) relative to the hydro-
phobic dansyl conjugates. But the much more substantial
increase was observed upon increasing the temperature, with
an ∼8 fold increase upon shifting from 20 °C to 37 °C
(entry 2). Further increases to the temperature could lead to
extremely rapid hydrolyses (entries 3 and 4); however, we
selected the optimised conditions as being 37 °C for 8.5 h.
Fig. 1 Hydrolysis rates of bromo- and thiomaleimides, measured by
‘turn-on’ of dansyl ﬂuorescence. t99% is the time taken for the hydrolysis
to be 99% complete.
Fig. 2 Incorporation of a PEG moiety into the reagent improves
eﬃciency of conjugation as observed by LCMS. Native HSA: 66 439 Da
(expected 66 439 Da); cysteine modiﬁcation: 66 694 Da (expected:
66 694 Da). UV absorbance measurements at 350 nm used to reveal
reaction progress.
Communication Organic & Biomolecular Chemistry
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This represented a reasonable timescale for the reaction,
whilst being conditions known to be well tolerated by protein
conjugates.
To further explore the eﬀect of linker design on hydrolysis, a
conjugate derived from the C-2-PEG reagent (conjugate 8) was
compared with a direct PEG (9) and a C-6-PEG (10) analogue. The
advantage of the electron-withdrawing C-2 moiety was clear, with
the hydrolysis occurring in just under 8 h compared to 74 h for
the direct PEG and 185 h for the C-6 analogue (Fig. 3).
With an optimised linker design established, we proceeded
to construct the albumin–paclitaxel conjugate. The synthesis
involved initial coupling of the PEG spacer to the MBM-C-2
acid 11, followed by a deprotection of the t-butyl ester and
coupling to paclitaxel (Fig. 4). MBM-Paclitaxel reagent 12 was
then conjugated to HSA, with post-conjugation hydrolysis
aﬀording the target conjugate 13. No detectable loss of
payload was observed during the hydrolysis step. As expected,
if no C-2 moiety was incorporated then prolonged incubation
at higher pH (6.5 h, pH 8.5, 37 °C) was required and >30% of
drug release was observed due to ester hydrolysis (ESI
Fig. S8†). It is interesting to note that HSA again serves a pro-
tective role in these conjugates, as closely related paclitaxel-
PEG esters have half-lives of 3–8 h at pH 7.4, 37 °C.25
To evaluate the albumin–paclitaxel conjugate (HSA-PTX)
cell killing potential, a MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) viability assay was performed to
measure the metabolic activity of a human breast cancer cell
line (MDA-MB-231-luc-D3H2LN)26 after treatment with either
free paclitaxel (PTX) or the HSA-PTX conjugate (Fig. 5). The
HSA-PTX conjugate performed similarly to that of free PTX,
with the minor reduction of in vitro cytotoxicity consistent
with comparable PTX–albumin pro-drug conjugates
reported.17 Notably the ester linkage in such paclitaxel conju-
gates is designed to release in the tumor environment, not
necessarily requiring internalisation. Indeed we confirmed
that this mechanism was likely to be contributing to this
in vitro cytotoxicity assay, as incubating the HSA-PTX conjugate
in the cellular media led to >50% ester hydrolysis in 48 h at
37 °C (ESI Fig S9†).
Conclusions
In conclusion, we have shown that monobromomaleimide-C-2-
PEG linkers oﬀer an ideal approach to generate serum stable
HSA conjugates. The UV absorbance of the thiomaleimides
formed upon conjugation can be used to reveal the rapid
nature of the reaction with Cys-34, and the subsequent rate of
stabilising hydrolysis. The protective nature of the Cys-34 cleft
is found to substantially reduce the speed of hydrolysis; but
with the inclusion of the electron withdrawing C-2 linker along
with conducting the reaction at 37 °C, pH 8.0, it is complete in
Fig. 3 Hydrolysis study on HSA-MBM conjugates, by monitoring loss of
absorbance at 350 nm. t99% is the time taken for the hydrolysis to be
99% complete.
Fig. 4 MBM-C-2-Paclitaxel synthesis and construction of albumin–
drug conjugate. Conjugate 13: 67 737 Da (expected 67 738 Da).
Fig. 5 MTT viability assay performed with MDA-MB-231-luc-D3H2LN
cells26 using either free paclitaxel (PTX) or HSA-paclitaxel (HSA-PTX)
conjugates at concentrations ranging from 5 nM–1000 nM after 48 h of
incubation. Data points represent the mean ± S.D (n = 3).
Organic & Biomolecular Chemistry Communication
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8 h. This optimisation allows the quantitative construction of
an HSA-paclitaxel conjugate without any hydrolysis of
the labile ester bond. Furthermore, the cytotoxicity of the
HSA-paclitaxel conjugate was retained, which combined with
the drug delivery properties of HSA indicates the potential of
this conjugate as a prospective anti-cancer therapeutic.
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